ReviewMolecular biology reports2022
The role and regulation of apoptosis signal-regulated kinase 1 in liver disease.
Review in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Updated insights on ASK1 signaling: mechanisms, regulation, and therapeutic potential in diseases.Molecular and cellular biochemistry · 2025Review
- Comprehensive Physiological and Transcriptomic Profiling of Triploid Pacific Oysters (Biology · 2025Article
- Aging, oxidative stress and degenerative diseases: mechanisms, complications and emerging therapeutic strategies.Biogerontology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
ASK1, also known as MAP3K5, plays a vital role in the MAPK pathway. The MAPK pathway has a variety of biological functions and plays an important role in regulating cell proliferation, differentiation, and apoptosis. Studies have shown that ASK1 is involved in apoptosis, inflammation, oxidative stress, and other processes and plays an essential role in various liver diseases. Therefore, ASK1 can be a therapeutic target for treating liver disease. Here, we initially summarized the effect of ASK1 on liver disease and described the differential regulation of ASK1, including phosphorylation, ubiquitination and methylation, by which the effects of ASK1 on some liver diseases can be inhibited. Although much has been discovered about the phosphorylation of ASK1, the effects of other post-transcriptional modifications on the activity of ASK1 require further exploration. We hope that by summarizing the existing regulatory mechanism we can shed new light on the research and provide new ideas for finding ASK1-targeting drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.